Andria Rae Crisler

I'll research this attorney's background and practice.

Andria Rae ("Rae") Crisler — Fish & Richardson (Dallas)

Focus areas. Crisler's practice is concentrated in pharmaceutical, biologic, and life-sciences patent litigation. Fish & Richardson's firm biography describes Hatch-Waxman work on products such as Odefsey, Descovy, and Vemlidy, BPCIA/biologics disputes, and treatment-method cases (schizophrenia, cardiac disease), alongside a secondary technical docket in semiconductor/system-on-chip power management and network and data-processing technologies. The firm bio also credits her with work on a multi-forum FRAND/SEP dispute for a large consumer electronics manufacturer spanning district courts, the ITC, and foreign venues, resolved by global settlement.

Side preference. Her tracked appearances are entirely defense-side (0 plaintiff, 2 defendant), and that pattern is consistent with the public docket record: she has acted for biosimilar applicants (Formycon, Samsung Bioepis) against Regeneron, for Samsung against the NPE Headwater Research, and for TalkDesk against Orion Labs. Nothing in the sources reviewed shows her as plaintiff's counsel in an affirmative infringement case, though her broader practice is best characterized as brand-vs.-biosimilar and operating-company defense work rather than a dedicated NPE/PAE prosecution practice.

Firm context. She is at Fish & Richardson, where she is now identified as a Principal in the Dallas office (Texas Bar No. 24093792); she had earlier been a summer associate at the firm. The tracked data lists her as "Of Counsel" on the Samsung Bioepis matter and "counsel" on the Formycon matter, which likely reflects an earlier title. Before private practice she clerked for Judge Gloria M. Navarro (D. Nev.) from 2015 to 2017.

Notable matters. Her two tracked cases are Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd. and Regeneron Pharmaceuticals, Inc. v. Formycon AG, both part of In re Aflibercept Patent Litigation (MDL 3103, N.D. W. Va.), the EYLEA biosimilar disputes over U.S. Patent No. 11,084,865. The district court granted preliminary injunctions against both defendants in June 2024; the Federal Circuit affirmed on January 29, 2025 (Nos. 24-1965 and 24-2009), upholding personal jurisdiction and rejecting obviousness-type double patenting and written-description challenges. Both cases later settled — Formycon in September 2025 and Samsung Bioepis in early 2026, with Samsung's injunction vacated and a January 2027 U.S. launch date. Public dockets also list her on Headwater Research LLC v. Samsung Electronics (E.D. Tex.), Communication Technologies, Inc. v. Samsung Electronics, and Orion Labs Tech, LLC v. TalkDesk, Inc.; Law360's firm profile shows a total of roughly 28 tracked patent matters.

PTAB/IPR. The record reviewed does not show her as named counsel on IPR or PGR petitions before the PTAB. Her verifiable post-grant exposure is on the district-court side of the IPR relationship — for example, supporting Samsung's motion to stay the Headwater case pending inter partes review (E.D. Tex. 2024) and authoring firm commentary on stays pending IPR and reexamination.

Bar / education. Admitted in Texas and Virginia; J.D., SMU Dedman School of Law (2015); B.S., University of Texas at Austin. Recognized in Best Lawyers: Ones to Watch since 2021. The public sources reviewed did not disclose additional bar admissions or Federal Circuit bar status.